Stuttgart - Delayed Quote EUR

AnaptysBio, Inc. (AN6.SG)

18.10 +0.60 (+3.43%)
At close: April 26 at 5:47 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
17,157.00
17,157.00
10,287.00
63,175.00
75,000.00
Operating Expense
174,229.00
174,229.00
125,441.00
119,989.00
98,879.00
Operating Income
-157,072.00
-157,072.00
-115,154.00
-56,814.00
-23,879.00
Net Non Operating Interest Income Expense
790.00
790.00
-13,558.00
-1,019.00
3,959.00
Other Income Expense
-7,341.00
-7,341.00
12.00
37.00
-11.00
Pretax Income
-163,623.00
-163,623.00
-128,700.00
-57,796.00
-19,931.00
Tax Provision
-4.00
-4.00
24.00
--
--
Net Income Common Stockholders
-163,619.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Diluted NI Available to Com Stockholders
-163,619.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Basic EPS
-5.42
-6.08
-4.57
-2.11
-0.73
Diluted EPS
-5.42
-6.08
-4.57
-2.11
-0.73
Basic Average Shares
27,390.25
26,924.00
28,165.00
27,431.00
27,302.00
Diluted Average Shares
27,390.25
26,924.00
28,165.00
27,431.00
27,302.00
Total Operating Income as Reported
-164,411.00
-164,411.00
-115,154.00
-56,814.00
-23,879.00
Total Expenses
174,229.00
174,229.00
125,441.00
119,989.00
98,879.00
Net Income from Continuing & Discontinued Operation
-163,619.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Normalized Income
-156,280.18
-156,280.18
-128,724.00
-57,796.00
-19,931.00
Interest Income
18,873.00
18,873.00
7,550.00
431.00
3,959.00
Interest Expense
18,083.00
18,083.00
21,108.00
1,450.00
--
Net Interest Income
790.00
790.00
-13,558.00
-1,019.00
3,959.00
EBIT
-145,540.00
-145,540.00
-107,592.00
-56,346.00
-19,931.00
EBITDA
-143,164.00
-143,164.00
-105,257.00
-54,256.00
-18,314.00
Reconciled Depreciation
2,376.00
2,376.00
2,335.00
2,090.00
1,617.00
Net Income from Continuing Operation Net Minority Interest
-163,619.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Total Unusual Items Excluding Goodwill
-7,339.00
-7,339.00
--
--
--
Total Unusual Items
-7,339.00
-7,339.00
--
--
--
Normalized EBITDA
-135,825.00
-135,825.00
-105,257.00
-54,256.00
-18,314.00
Tax Rate for Calcs
0.00
0.00
0.00
--
--
Tax Effect of Unusual Items
-0.18
-0.18
--
--
--
12/31/2020 - 10/12/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TARA Protara Therapeutics, Inc.
2.9250
-4.10%
 
XNCR Xencor, Inc.
19.98
+3.90%
 
MORF Morphic Holding, Inc.
28.07
+0.32%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
GLPG Galapagos NV
28.76
+0.45%
 
ANAB AnaptysBio, Inc.
21.00
+11.29%
 
PRTA Prothena Corporation plc
20.87
+1.51%
 
RLFTF Relief Therapeutics Holding SA
1.4500
0.00%
 
ARVN Arvinas, Inc.
32.37
+2.44%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.6375
+1.21%